Healthcare Services

Type 2 Diabetes Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Type 2 Diabetes Market From 2026 To 2030?

The type 2 diabetes market has experienced robust expansion in recent years. It is projected to expand from $51.47 billion in 2025 to $55.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to the rising global prevalence of obesity, increasingly sedentary lifestyles, the broader availability of oral antidiabetic drugs, growing screening efforts for metabolic disorders, and improved access to primary diabetes care.

The type 2 diabetes market size is anticipated to undergo significant expansion in the upcoming years. It is projected to reach $78.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion over the forecast period can be attributed to several factors, including an increased demand for weight-management focused therapies, a growing adoption of personalized diabetes treatment plans, the spread of digital therapeutic platforms, a heightened focus on preventive diabetes management, and increased investments in next-generation antidiabetic drugs. Notable trends during this period are expected to include the rising adoption of GLP-1 receptor agonists, an increased emphasis on cardiometabolic risk management, the broader use of combination drug therapies, the development of lifestyle-integrated treatment approaches, and a stronger focus on long-term glycemic control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Drivers Are Influencing The Type 2 Diabetes Market?

The increasing prevalence of obesity and heart disease is anticipated to propel the expansion of the type 2 diabetes market in the future. Obesity is a medical condition defined by an unhealthy accumulation of excess body fat, whereas heart disease encompasses various conditions affecting the heart and blood vessels. Elevated body weight raises the risk of insulin resistance, leading to high blood sugar levels and the subsequent development of type 2 diabetes. Conversely, high blood sugar levels can damage blood vessels and nerves that control the heart and blood vessels, potentially resulting in heart disease. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people globally were grappling with obesity. This included 2.5 billion adults (aged 18 years and older) who were overweight, with 890 million of them living with obesity. Among adults, 43% were considered overweight, and 16% were categorized as obese. Furthermore, the number of overweight children under the age of 5 reached 37 million. Thus, the rising rates of obesity and heart disease are driving the growth of the type 2 diabetes market.

Which Segments Are Included In The Analysis Of The Type 2 Diabetes Market?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin, Buformin, Phenformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What Trends Are Affecting The Expansion Of The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are concentrating on creating advanced solutions, such as expanded-indication SGLT2/GLP-1 combination therapies, to achieve improved glycemic control, mitigate comorbidities, and boost patient adherence. These expanded-indication SGLT2/GLP-1 combination therapies represent drug regimens that integrate sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (or their fixed-dose combinations) to address blood glucose management, obesity, and cardiovascular and renal health in individuals with type 2 diabetes concurrently. For example, in June 2024, the UK-based pharmaceutical firm AstraZeneca secured U.S. FDA approval for Farxiga (dapagliflozin) for the paediatric type 2 diabetes indication (age 10 years and older), thereby extending its application beyond adult populations and indicating a wider patient outreach approach. This particular advancement provides once-daily oral administration for younger patients, includes data on cardiometabolic and renal protection, and facilitates market entry into paediatric and early-stage type 2 diabetes sectors, thereby fueling expansion in the global type 2 diabetes market.

Which Key Industry Participants Are Active In The Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc, Novartis AG, AstraZeneca plc, Abbott Laboratories, Sanofi SA, Medtronic plc, Takeda Pharmaceutical Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd, Boehringer Ingelheim International GmbH, Dexcom Inc, Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health

Read the full type 2 diabetes market report here:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the type 2 diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Type 2 Diabetes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Browse Through More Reports Similar to the Global Type 2 Diabetes Market 2026, By The Business Research Company

Type 1 Diabetes Global Market Report

https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Antidiabetics Global Market Report

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Diabetes Care Devices Market

https://www.thebusinessresearchcompany.com/report/diabetes-care-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795